Endocrine Abstracts

GH deficiency (GHD) in adults leads to impairment in body composition and function, as well as to deranged lipoprotein and carbohydrate metabolism implying increased cardiovascular morbidity. The morphologic and metabolic alterations in GHD syndrome are more marked in patients with the most severe GHD, even when evaluated by maximal provocative test such as GHRH + arginine. IGF1 synthesis and secretion are function of the GH status but also of major metabolic factors such as i...

Context: Glucocorticoids are known to decrease protein synthesis and impair membrane excitability of muscle fibres. However, their short-term effects on muscle structure and function of healthy subjects remain poorly understood.Objective: To investigate whether steroid administration could decrease the circulating levels of muscle proteins and modify myoelectric indexes of sarcolemmal excitability and fatigability.Design: Single-bl...

ITT is the test of reference for the diagnosis of adult GH deficiency (GHD), but it is recognized that also GHRH in combination with arginine (ARG) or GH secretagogues (GHS) are equally reliable tests. It has also been suggested that testing with GHS would represent a potent stimulus exploring also the integrity of hypothalamic pathways controlling somatotropic function. We therefore aimed to clarify the diagnostic reliability of testing with ghrelin, the natural GHS. We studi...

HPA is negatively regulated by glucocorticoid feed-back at hypothalamic, pituitary and hippocampal level by glucocorticoid (GR) and mineralcorticoid (MR) receptors. MR antagonists impair HPA rhythm after acute administration. The aim of this study was to verify HPA activity and glico-insulinemic profile both basally and after acute administration of potassium canrenoate (CAN), before and after chronic treatment. We evaluated ACTH, cortisol (F) and dehydroepiandosterone (DHEA) ...

Introduction: Nitric oxide (NO) plays a wide spectrum of biological actions including a positive role in oocyte maturation and ovulation. Free radicals have been shown elevated in PCOS and therefore would be responsible for quenching NO that, in turn, would play a role in determining oligo or amenorrhea connoting PCOS. We recently demonstrated that the combined administration of N-acetylcysteine (NAC) and arginine (ARG) is able to exert an antioxidant action leading to ...

Clinically silent adrenal masses discovered by abdominal imaging procedures performed for non-adrenal disorders, i.e. adrenal incidentalomas, have become a common finding in clinical practice and they represent a clinical concern because of the risk not only of malignancy but also of subclinical hormonal hypersecretion (SCS) that represents a new risk factor for cardiovascular diseases and/or osteoporosis. We studied 73 patients (39F, 34M; mean±S.E.M.: 61.6...

Object: In Addison’s disease hydrocortisone or cortisone have so far been used at doses of 30–37.5 mg/day, respectively, though several studies showed that cortisol normal production is about 5.7 mg/m2 (20–25 mg/day of hydrocortisone or cortisone, respectively). Differently from secondary hypoadrenalism, scanty data exist in patients with Addison’s disease on role of conventional glucocorticoid replacement and metabolic and cardiovascular outcome...

Growth hormone releasing hormone (GHRH) is a neuropeptide mainly synthesised in the hypothalamus, known to exert a stimulatory effect on the synthesis and release of growth hormone (GH) from the pituitary via the activation of specific receptors. New data indicate that GHRH is also produced in both extrahypothalamic brain areas and in peripheral tissues. GHRH-receptor splice variants (SVs) have been found in several peripheral normal and neoplastic human tissues and mediate ef...

The hypothalamic hormone growth hormone-releasing hormone (GHRH), has been shown to function via its receptor splice variants as an autocrine/paracrine growth factor in normal and malignant cell lines and tissues, besides positively regulating growth hormone (GH) synthesis and secretion from the pituitary. Moreover, GHRH antagonists are known to suppress the proliferation of a wide variety of cancer cells through mechanisms yet to be fully elucidated. Aim of this study was to ...

In acromegalic patients not suitable for first-line surgical treatment, pharmacotherapy is a valuable choice. Depot somatostatin analogs (SSA) represent efficacious and well-tolerated drugs; however, they normalize hormonal parameters in no more than 65–75%. Pegvisomant (PEGA), a GH receptor antagonist, has been shown to normalize IGF-I levels in more than 90% of patients. We report our experience in 13 acromegalic patients (7 M, 6 F; age: 50.2±3.9 yrs; 7 macroadenom...